Literature DB >> 21669567

Necessity and indications of invasive treatment for Budd-Chiari syndrome.

Yang Fu1, Yu-Ling Sun, Xiu-Xian Ma, Pei-Qin Xu, Liu-Shun Feng, Zhe Tang, Sheng Guan, Zhi-Wei Wang, Cheng-Han Luo.   

Abstract

BACKGROUND: The development of collaterals in Budd-Chiari syndrome has been described and these collaterals play an important role in the presentation of this disease. These collaterals are diagnostic and their use in management strategy has never been evaluated. This study aimed to investigate the indications, feasibility and necessity of invasive treatment for patients with Budd-Chiari syndrome and to determine whether such a strategy is necessary for optimal management.
METHODS: Twenty-nine patients who had been treated at our unit were enrolled in this study. Based on physical and biochemical examination, and hemodynamic compensation by collaterals, 18 patients underwent radiological intervention (group A), while the other 11 had no invasive treatment (group B). The related hemodynamic parameters were acquired when percutaneous angiography was performed.
RESULTS: In group A, all patients underwent successfully inferior vena cava (IVC) balloon angioplasty with or without stenting. Four patients also underwent hepatic vein angioplasty. In these patients, the mean IVC pressure before and after treatment was statistically different (29.3+/-9.2 vs 15.1+/-4.6 mmHg, P<0.01). The mean IVC pressure was much lower in group B than in group A (12.9+/-2.4 vs 29.3+/-9.2 mmHg, P<0.01), but there was no difference from that of the patients after radiological treatment (12.9+/-2.4 vs 15.1+/-4.6 mmHg, P>0.05). Median follow-up was 32.3 months (mean 21.3 months; range 3-61 months). In the course of follow-up, the patients in group A survived with good systemic status except for re-stenosis in one patient who underwent re-canalization of the IVC. In group B, 10 patients had good systemic status except one patient who had a meso-caval shunt because of deterioration.
CONCLUSIONS: The rationale of "early diagnosis and early treatment" is not suitable for all patients with Budd-Chiari syndrome. Satisfactory survival can be achieved in some patients without invasive treatment, who are completely compensated by rich collaterals. Nonetheless, a positive treatment procedure should be performed if the patient's situation worsens in the course of regular follow-up.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21669567     DOI: 10.1016/s1499-3872(11)60042-8

Source DB:  PubMed          Journal:  Hepatobiliary Pancreat Dis Int


  6 in total

Review 1.  Collateral pathways in portal hypertension.

Authors:  Malay Sharma; Chittapuram S Rameshbabu
Journal:  J Clin Exp Hepatol       Date:  2012-12-16

2.  Endovascular stenting of the inferior vena cava in a patient with Budd-Chiari syndrome and main hepatic vein thrombosis: a case report.

Authors:  Young-In Yoon; Shin Hwang; Gi-Young Ko; Tae-Yong Ha; Gi-Won Song; Dong-Hwan Jung; Young-Sang Lee; Sung-Gyu Lee
Journal:  Korean J Hepatobiliary Pancreat Surg       Date:  2015-02-28

3.  Specific alterations in gut microbiota are associated with prognosis of Budd-Chiari syndrome.

Authors:  Yu-Ling Sun; Wen-Qi Li; Peng-Xu Ding; Zhi-Wei Wang; Chang-Hua Wei; Xiu-Xian Ma; Rui-Fang Zhang; Yan Wu; Lin Zhou; Ruo-Peng Liang; Yan-Peng Zhang; Yi-Pu Zhao; Rong-Tao Zhu; Jian Li
Journal:  Oncotarget       Date:  2017-12-14

4.  Significance of malondialdehyde, superoxide dismutase and endotoxin levels in Budd-Chiari syndrome in patients and a rat model.

Authors:  De-Lei Cheng; Nan Zhu; Cheng-Li Li; Wei-Fu Lv; Wei-Wei Fang; Ya Liu; Chuan-Ting Li
Journal:  Exp Ther Med       Date:  2018-10-09       Impact factor: 2.447

5.  Usefulness of Venous Pressure Measurement in Endovascular Treatment of Budd-Chiari Syndrome: A Retrospective Cohort Study.

Authors:  Ken Kageyama; Akira Yamamoto; Atsushi Jogo; Takehito Nota; Kazuki Murai; Satoyuki Ogawa; Mariko M Nakano; Etsuji Sohgawa; Shinichi Hamamoto; Masao Hamuro; Toshio Kaminou; Norifumi Nishida; Kanae Takahashi; Kouji Yamamoto; Yukio Miki
Journal:  Intern Med       Date:  2019-06-27       Impact factor: 1.271

6.  Evaluation of outcome from endovascular therapy for Budd-Chiari syndrome: a systematic review and meta-analysis.

Authors:  Gauri Mukhiya; Xueliang Zhou; Xinwei Han; Dechao Jiao; Gaurab Pokhrel; Yahua Li; Sita Pokhrel
Journal:  Sci Rep       Date:  2022-09-28       Impact factor: 4.996

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.